Clinical trial NCT02000388: Intranasal Ketorolac Tromethamine (SPRIX) as a Short Term Pain Management of Post-Vasectomy Pain
Official title: Efficacy and Safety of Intranasal Ketorolac Tromethamine (SPRIX) as a Short Term Pain Management Tool for Adult Male Patients With Post-Vasectomy Pain
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Post Vasectomy Pain
Lead sponsor: Citrus Valley Medical Research, Inc.
Sponsor class: OTHER
First posted: 2013-12-04
Enrollment: 15
Sex: MALE
Minimum age (years): 25
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy, tolerability and safety of intranasal ketorolac tromethamine (SPRIX) as an option for pain management in post vasectomy patients.


Eligibility criteria: INCLUSION CRITERIA

1. Male Subject must be between the age twenty five (25) years and sixty four (64)
2. Willing and able to provide an informed consent
3. Has made decision to undergo vasectomy
4. Subject is in good general physical condition as assessed by the Principal Investigator

EXCLUSION CRITERIA

1. Current treatment with or known allergy or sensitivity to all forms of ketorolac tromethamine , aspirin , other non steroidal anti inflammatory drugs (NSAIDs) or Ethylenediaminetetraacetic acid (EDTA)
2. Use of narcotics/opiate or medical marijuana within one (1) week prior to the baseline visit and entire study participation
3. Use of illegal drugs by self reporting
4. History of drug or alcohol abuse within five (5) years of screening visit
5. History of suicide attempt within five (5) years of screening visit
6. A diagnosis of a severe neuro-psychiatric disease
7. Subject who is currently receiving investigational drug(s) or participated in a clinical trial involving investigational drug(s) within thirty (30) day of the screening visit
8. Subject with history of any of the following coronary conditions: (chronic stable angina being currently treated with long acting nitrates, chronic stable angina require treatment with short acting nitrates with 90 days of visit 1, angina occurring during sexual intercourse in the last six months, unstable angina within six months of visit 1
9. Resting, sitting blood pressure (BP) \> 160mm Hg in systolic pressure or \> 100mm Hg is diastolic pressure at screening. If a patient is found to have untreated significant hypertension at screening and antihypertensive treatment is initiated, assessment for study eligibility should be deferred until BP and antihypertensive medication have been stable for at least one month. For patients with previously diagnosed hypertension, antihypertensive medications must be stable for at least one month prior to screening.
10. Known or suspected cerebrovascular bleeding, hemorrhagic diathesis or incomplete hemostasis, and those at high risk of bleeding, have history of a bleeding problem or low platelet count or coagulation disorder or are on therapy that affects homeostasis
11. Active peptic ulcer disease, recent GI bleeding or perforation, or a history of peptic ulcers or GI bleeding
12. History of asthma, urticaria or other allergic-type reaction after taking aspirin or other non steroidal inflammatory drugs (NASIDs)
13. Subject over sixty four (64) years of age
14. Subject with any clinically significant renal function or liver abnormality
15. Subject who has history of swelling of face, mouth, tongue, lips, gums, neck, or throat (angioedema) or with cardiac decompensation or similar conditions
16. Major surgery scheduled within 3 weeks or screening and for entire participation of study
17. Current exfoliative dermatitis, Stevens-Johnson syndrome or toxic epidermal necrolysis
18. Any condition in the opinion of the investigator that makes the subject unsuitable for study

    -

Primary outcomes:
measure: Pain Scores on the Visual Analog Scale
timeFrame: 5 days
Secondary outcomes:
measure: To determine Number of Participants with Adverse Events as a Measure of Safety and Tolerability
timeFrame: 5 Days
Other outcomes:
Locations:
Study officials:
affiliation: Citrus Valley Medical Research, Inc.
name: Edward L Davis, M.D.
role: PRINCIPAL_INVESTIGATOR
References: